Exploring GT Biopharma, Inc. (GTBP) Investor Profile: Who’s Buying and Why?

Have you ever wondered who's investing in GT Biopharma, Inc. (GTBP), a clinical-stage biopharmaceutical company focused on innovative immuno-oncology therapies? As of April 8, 2025, GT Biopharma's share price stood at $2.33, a change from $4.17 on April 9, 2024. Delving into the investor profile reveals that 25 institutional owners and shareholders hold a total of 1,256,726 shares. Curious about which major players are making moves and what's driving their investment decisions in this NASDAQ-listed company with a market cap of $5.71 million? Keep reading to find out!

GT Biopharma, Inc. (GTBP) Who Invests in GT Biopharma, Inc. (GTBP) and Why?

Understanding the investor profile of GT Biopharma, Inc. (GTBP) provides valuable insights into the market's perception of the company and its future prospects. Investors are typically categorized into retail investors, institutional investors, and hedge funds, each bringing different strategies and motivations.

Key Investor Types

The investor base of GT Biopharma, Inc. (GTBP) can be broken down into several key types:

• Retail Investors: These individual investors often trade in smaller volumes and may be influenced by factors such as news releases, online forums, and personal investment strategies.
• Institutional Investors: These include entities such as mutual funds, pension funds, and insurance companies. They typically invest larger sums of money and conduct extensive due diligence before investing.
• Hedge Funds: These funds employ more aggressive strategies, including short-term trading and leveraging, and may invest in GT Biopharma, Inc. (GTBP) based on speculative opportunities.

Investment Motivations

Different factors attract various investors to GT Biopharma, Inc. (GTBP):

• Growth Prospects: Many investors are drawn to GT Biopharma, Inc. (GTBP) because of its potential for growth in the biotechnology sector, particularly its focus on innovative cancer therapies.
• Market Position: The company's position in the competitive landscape of cancer treatment and its proprietary technology platforms may attract investors looking for unique opportunities.

Investment Strategies

Investors in GT Biopharma, Inc. (GTBP) adopt a variety of strategies, influenced by their investment goals and risk tolerance:

• Long-Term Holding: Some investors, particularly institutional ones, may adopt a long-term holding strategy, banking on the company’s sustained growth and success over time.
• Short-Term Trading: Hedge funds and some retail investors may engage in short-term trading, capitalizing on stock price volatility and news-driven events.
• Value Investing: Investors employing a value investing approach may see GT Biopharma, Inc. (GTBP) as undervalued, with potential for significant returns as the company’s true worth is recognized by the market.

A closer look at GT Biopharma, Inc. (GTBP)'s ownership structure reveals the mix of investor types and their influence on the company. While specific recent data on exact ownership percentages can fluctuate, examining filings and major investment news can provide a clearer picture.

Understanding the motivations and strategies of these key investor types is crucial for anyone looking to analyze or invest in GT Biopharma, Inc. (GTBP). Each group brings its own perspective and can significantly impact the company's stock performance and overall market perception.

To gain a deeper understanding of GT Biopharma, Inc. (GTBP), explore its history, mission, and ownership details: GT Biopharma, Inc. (GTBP): History, Ownership, Mission, How It Works & Makes Money

GT Biopharma, Inc. (GTBP) Institutional Ownership and Major Shareholders of GT Biopharma, Inc. (GTBP)

Understanding the institutional ownership and major shareholders of GT Biopharma, Inc. (GTBP) can provide valuable insights into the company's stability, investor confidence, and potential future performance. Institutional investors, such as mutual funds, hedge funds, and pension funds, often have significant resources and expertise to conduct thorough research, making their investment decisions noteworthy for other investors.

While up-to-date, precise figures for 2024 GT Biopharma, Inc. (GTBP) shareholdings may vary and require real-time financial data sources, examining earlier trends and reports can offer a general understanding of the landscape. Keep in mind that ownership percentages can shift due to buying and selling activities.

Here are key aspects to consider regarding institutional ownership in GT Biopharma, Inc. (GTBP):

• Top Institutional Investors: Identifying the top institutional investors provides insight into who the major players are. These firms typically manage large portfolios and their investment decisions can have a notable impact.
• Shareholding Trends: Monitoring whether institutional investors have been increasing, decreasing, or maintaining their positions can indicate sentiment towards the stock. An increase in institutional ownership might suggest growing confidence in the company's prospects.
• Impact on Stock Price and Strategy: Large institutional investors can influence GT Biopharma, Inc. (GTBP)'s stock price through their trading activity. Additionally, their engagement with company management can potentially influence corporate strategy.

To get the most current data, refer to financial news sources and investor relations sections of GT Biopharma, Inc. (GTBP)’s website.

For more in-depth background information, you might find this resource helpful: GT Biopharma, Inc. (GTBP): History, Ownership, Mission, How It Works & Makes Money

GT Biopharma, Inc. (GTBP) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of GT Biopharma, Inc. (GTBP) provides crucial insights into the company's stability, growth potential, and strategic direction. Examining who invests in GT Biopharma and why can reveal a lot about the market's perception of the company. GT Biopharma, Inc. (GTBP): History, Ownership, Mission, How It Works & Makes Money

As of April 2025, 25 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 1,256,726 shares. Institutional ownership accounts for approximately 49.13% of the shares held. It's also important to note that 18.13% of shares are held by insiders, while a significant 98.47% is owned by public companies and individual investors.

Here’s a breakdown of some notable investors:

• DekaBank Deutsche Girozentrale: Holds 1.15 million shares, representing approximately 45.53% of the company.
• Bank of Montreal /CAN/: Holds 28.95k shares, amounting to about 1.14%.
• Geode Capital Management, LLC: Owns 14.9k shares, which is around 0.59%.
• Vanguard Group Inc: Holds 10.5k shares, representing about 0.41%.
• Wells Fargo & Company: Owns 10.01k shares, accounting for approximately 0.39%.
• BlackRock Inc.: Holds 9.74k shares, or about 0.38%.
• UBS Group AG: Possesses 5k shares, representing 0.20%.

Mutual fund holders include:

• Fidelity Concord Street Trust-Fidelity Extended Market Index Fund: Holds 10.8k shares, accounting for approximately 0.43%.
• VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund: Holds 10.5k shares, representing about 0.41%.

These institutional investors can exert influence through:

• Voting Rights: Large institutional holders possess significant voting power, enabling them to influence company decisions such as board member elections, executive compensation, and major strategic initiatives.
• Market Sentiment: Substantial buying or selling by these investors can impact stock prices, influencing market sentiment and attracting or deterring other investors.
• Activism: Some institutional investors may engage in shareholder activism, pushing for changes in company policies or strategic direction to enhance shareholder value.

Recent moves by GT Biopharma include:

• Issuing a pre-funded warrant to Cytovance Biologics, Inc. for 326,251 shares of common stock as compensation for services rendered.
• Entering agreements for the exercise of warrants to purchase 302,069 shares of common stock at a reduced price of $2.27 per share.
• Withdrawing its Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission, initially filed on December 23, 2024.

GT Biopharma's key statistics as of April 2025 include:

The Fund Sentiment Score, which assesses the level of institutional accumulation, ranges from 0 to 100, with higher numbers indicating greater accumulation. As of April 2025, GT Biopharma's fund sentiment score reflects ongoing institutional interest and activity in the stock.

Overall, the investor profile of GT Biopharma, Inc. (GTBP) indicates a mix of institutional and individual investors. Recent stock performance shows a -40.42% decrease over the last year. The next earnings report is expected on May 19, 2025. Recent news includes positive sentiment from new trial results and milestones in their GTB-3650 Phase 1 trial.

GT Biopharma, Inc. (GTBP) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to GT Biopharma, Inc. (GTBP) is crucial for assessing the company's current standing and future prospects. Examining major shareholders' perspectives, recent market behaviors, and analyst insights provides a comprehensive view of the factors influencing GTBP's stock performance.

Investor sentiment toward GT Biopharma, Inc. (GTBP) can be gauged by analyzing the positions of major shareholders. While specific sentiments (positive, neutral, or negative) aren't always explicitly stated, changes in holdings and trading activity can offer clues. Increased buying activity may indicate a positive outlook, while selling may suggest concerns. It's important to consider the context of these actions, such as overall market conditions and company-specific news.

The stock market's response to shifts in ownership or significant investor actions can be a telling sign. For example, a large institutional investor taking a new position in GT Biopharma, Inc. (GTBP) might lead to a stock price increase, reflecting confidence in the company's potential. Conversely, a major investor reducing their stake could trigger a price decline. These reactions aren't always immediate or directly proportional, as they can be influenced by broader market trends and investor psychology.

Analyst perspectives play a vital role in interpreting the impact of key investors on GT Biopharma, Inc.'s (GTBP) future. Analysts often provide insights into how changes in ownership structure or investor behavior might affect the company's strategy, financial performance, and long-term growth prospects. These insights can help investors understand the potential risks and opportunities associated with GTBP.

To gain deeper insights into GT Biopharma, Inc.'s (GTBP) strategic direction, explore their Mission Statement, Vision, & Core Values of GT Biopharma, Inc. (GTBP).

For example, if a major pharmaceutical company acquires a significant stake in GT Biopharma, Inc. (GTBP), analysts might view this as a positive sign, suggesting validation of GTBP's technology or pipeline. This could lead to increased investor interest and a higher stock valuation. However, analysts might also raise concerns about potential conflicts of interest or the impact on GTBP's independence.

Below is an example table that illustrates potential impacts of investor actions on GT Biopharma, Inc. (GTBP):

Keeping abreast of these dynamics requires continuous monitoring of financial news, regulatory filings, and analyst reports. Understanding the interplay between investor sentiment, market reactions, and expert analysis is essential for making informed decisions about GT Biopharma, Inc. (GTBP).